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Some countries’ pharmaceutical benefits programs such as Australia, Canada, or
U.S. listed DEs for pancreatic insufficiency due to chronic pancreatitis, carcinoma
of the pancreas, or cystic fibrosis, however, those reimbursed by Taiwan NHI had
broader scope of indications. In addition to more medical orders prescribed by
varied health care specialties, we observed the expenditure increased by approxi-
mately two times over the past 10 years.
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OBJECTIVES:Knowledge and practice of disposal of date expired and unused drugs
among college students and people having a health science background and to find
the most widely used method of drug disposal for the expired drugs in the study
group.METHODS:Apilot study questionnairewas prepared and a surveywas done
among students with Health Science background to understand the appropriate-
ness of content. Further 500University students andpeople having ahealth science
background were interviewed personally using the validated questionnaire pre-
pared. Results were presented percentage responses and interpretation of the re-
sults helped in the derivation of the final conclusion. RESULTS:When asked about
the awareness of the existing guidelines for the safe disposal of drugs in various
countries 56% of the respondents knew about it while 44%were unaware. A total of
52.2% of the respondents agreed that the wrong drug disposal methods can lead to
adverse environmental effects while 25.6% strongly agreed to it. A mere 4.8% dis-
agreed to the statementwhile another 17.4% somewhat agreed to it; 56.8% strongly
agreed to the fact that there was a need of a drug take back system in their place of
residence. A total of 57.2% opined that there was a need of public awareness pro-
grams to increase the awareness about drug disposal in the general public. A ma-
jority 91.2% of the respondents admitted that they simply throw the expired drugs
into the dustbins. 46.8% of the people said there was no work being done in this
context by any organization. CONCLUSIONS: The study clearly indicates lack of
awareness and good practices of date expired drugs among surveyed population.
There is a need to create awareness regarding disposal of drugs among the popu-
lation which should be done either by the government or any organization.
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OBJECTIVES: Adequate use of antimicrobial agent is critical issue in hospital. It
would enlarge the burden, for instance increase medical expenditure and antimi-
crobial resistance rate, if misuse. To evaluate the annual use of the third line
antibiotic agents - fluoroquinolones, including ciprofloxacin, moxifloxacin and
levofloxain, and that could be took a reference to manage the use in a regional
teaching hospital.METHODS: The data, including patient-days and the consump-
tion quantity of ciprofloxacin, moxifloxacin and levofloxain, was extracted
monthly from Hospital Information System of a regional teaching hospital from
January 2010 to December 2011. Consumption quantity was transferred to
“1000DDD /patient-days”. Data management and analysis was performed using
student t test. RESULTS:Number of 1000DDD /patient-days in all fluoroquinolones
were 202.47 in 2010, 202.47 in 2022 and there was no significantly difference
(p0.067). Number of 1000DDD /patient-days in ciprofloxacin significantly de-
creased (p 0.0023) in 2011(1000DDD /patient-days 127.35) comparing with 2010
does (1000DDD /patient-days 181.69). Number of 1000DDD /patient-days inmoxi-
floxacin were 38.95 in 2010 and 48.08 in 2011. In the aspect of levofloxacin, number
of 1000DDDwere 25.46 in 2010 and 27.03 in 2011. The number of 1000DDD /patient-
days in Moxifloxacin and levofloxacin both were no significantly difference be-
tween 2011 and 2010. CONCLUSIONS: The fluoroquinolones consumption de-
creased especially on ciprofloxacin, but the levofloxacin and moxifloxacin mild
increased. Although no significantly difference on the amount of all fluoroquino-
lones between 2010 and 2011may be good and stand for well control. But extenting
the study to the outcomes of infection control and the association of the culture
results would be more objective.
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OBJECTIVES: To identify the nature and frequency of DRPs (drug interaction and
irrational dose), and their impacts on length of stay (LOS) of patients with chronic
kidney disease (CKD) stage 4 and 5 hospitalized in Haji AdamMalik (HAM) Hospital,
Indonesia. METHODS: This retrospective cohort study was conducted on 80 pa-
tients based on JAMKESMAS database for 6-month period (October 2009 - March
2010). Inclusion criteria were patients administered antibiotics and GFR of 30
mL/min/1.73 m2. Exclusion criteria were patients under 18 years old, patients with
cancer, and patient with Human Immunodeficiency Virus (HIV). Data collected
include type of drugs administered, laboratory tests, and clinical outcomes. Iden-
tification of drug interaction and analysis of antibiotics dose rationality were per-
formed using Stockley’s drug interactions, Medlines, and Handbook of Clinical
Drug Data. The impacts of DRPs on LOS were performed by multiple linear regres-
sion analysis. RESULTS: Of the sample, male was 66% and female was 34%; CKD
stage 4 was 17% and CKD stage 5 was 83%. Most drug interactions were between
NSAIDs and ACE inhibitor, ranitidine and furosemide, ranitidine and ciprofloxacin,
metoclopramide and NSAIDs, dexamethasone and furosemide, NSAIDs and furo-
semide.Mean value of drug interactionwas 1 1.31.Most frequent irrational doses
of antibiotics involved ceftriaxone, ceftazidime, cefadroxyl, ciprofloxacin, and
amoxicillin. Mean value of irrational doses was 0.43  0.67. Means of LOS was
6.645.76.Multiple linear equation obtained: y 3.91 2.16x1 0.97x2; y LOS; x1
 drug interaction; x2 irrational dose of antibiotics. CONCLUSIONS: This finding
must be highlighted and considered to optimize treatment of CKD. Impact of drug
interaction on LOS of CKD patients was higher compared to that of irrational dose
of antibiotics.
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OBJECTIVES: Although most of the medications containing herbal extracts have
been used in the treatment of diseases for many years, the evidence on the clinical
efficacy and safety are still in controversy. It is necessary to conduct an evaluation
on these products.METHODS: First, we defined the medications containing herbal
extracts in this study, aswell as identified the items reimbursed inNational Health
Insurance. In the next step, we analyzed the 2001-2007 National Health Insurance
Research Database (NHIRD) to find themost frequently used items in the category.
Silymarin was identified as the most used during 2001-2007. We conducted the
literature search and review on the clinical effectiveness of the ingridient.
RESULTS: In this review, we summarized the reports published by the literature.
These reports had systematically reviewed on the topic of the effectiveness of
silymarin in patients with alcoholic and /or hepatitis B or C liver diseases. In the
report by The Cochrane Collaboration - a total of thirteen randomized trials as-
sessed silymarin in patients with alcoholic and /or hepatitis B or C liver diseases
were included in the meta-analysis. Results from these trials showed a significant
effect of silymarin on liver-related mortality (RR 0.50, 95% CI 0.29 - 0.88), but no
significant effects could be demonstrated if the analysis were restricted on only
high quality trials (RR 0.57, 95% CI 0.28 - 1.19). For the resource utilization of sily-
marin, we found that the total claims on silymarin increased 59.83% fromyear 2001
to 2007. CONCLUSIONS: As mentioned above, the effectiveness of silymarin in
patients with liver disease has not been established. Further studies on mecha-
nisms of action, as well as related well-designed clinical trials are needed.
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OBJECTIVES: To quantify the association between disability and prescriptionmed-
ication use among older adults. Individuals with disability may consume more or
varying types of prescription medication, thereby requiring special services.
METHODS: Data from the nationally-representative Health and Retirement Study
2006 and the Prescription Drug Study 2007 in the United States were used to exam-
ine associations between disability and prescription medication use among 2,755
adults. The dependent variable, disability versus no disability, was determined
based on responses to questions assessing functional, mobility, and cognitive sta-
tus. Subjects responding affirmatively to one of these types of disabilities were
classified as disabled. Chi-square tests assessed the dependent categorical vari-
ables by disability. Negative binomial regressions were used to examine the rela-
tionship between disability and prescriptionmedication use, controlling for acces-
sibility, affordability, beliefs in medication, health conditions and socio-
demographic variables. RESULTS: Of the 2,755 subjects, 70.8% were classified as
disabled. Female, older, non-white, widowed, less educated, living in rural area,
lower income, having three chronic diseases, poor health status, no alcohol or
smoking habits, hardly exercise, taking prescription drugs regularly, and consult-
ing with medical doctors more were all statistically significant variables indicative
of greater risk of disability (P0.0001). Subjects classified as disabled [IRR1.09 (95%
CI, 1.03-1.15)], with three or more chronic conditions [IRR2.08 (95% CI, 1.93-2.35)],
not exercising [IRR1.08 (95% CI, 1.04-1.10)], taking medications regularly
[IRR1.85 (95% CI, 1.51-2.27)] and sevenmore times doctor visits [IRR1.46 (95% CI,
1.36-1.57)] had a greater incidence of prescription medication uses. Subjects with
lower income [IRR0.99 (95% CI, 0.99-0.99)], no alcohol or smoking habits [IRR0.93
(95% CI, 0.88-0.98)] had a lower incidence likelihood of prescription medication
uses. CONCLUSIONS:Disability was a statistically significant predictor of prescrip-
tion medication use. Further research is necessary to examine the associations
between specific disability types and medications use.
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OBJECTIVES: Compare oral 5-aminosalicylic acid (5-ASA) treatment persistence
and adherence in patients with mild/moderate ulcerative colitis (UC). METHODS:
IMS LifeLink™Health Plan claims datawere analyzed to identify patients18 years
with 1 UC diagnosis (ICD-9-CM: 556.x) and had 1 prescription for 5-ASA (sul-
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